• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Information Quality in Regulatory Decision Making: Peer Review versus Good Laboratory Practice.监管决策中的信息质量:同行评审与良好实验室规范。
Environ Health Perspect. 2012 Jul;120(7):927-34. doi: 10.1289/ehp.1104277. Epub 2012 Feb 17.
2
Quality science and quality assurance: observations of an environmental scientist.质量科学与质量保证:一位环境科学家的观察
Qual Assur. 1999 Oct-Dec;7(4):225-35. doi: 10.1080/105294199750061344.
3
Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies.科学和监管政策委员会关注要点:审查美国食品和药物管理局(FDA)关于非临床毒理学研究中病理学同行评审的指南。
Toxicol Pathol. 2024 Feb;52(2-3):138-148. doi: 10.1177/01926233241248654. Epub 2024 Jun 6.
4
Scientific and Regulatory Policy Committee Review: Review of the Organisation for Economic Co-operation and Development (OECD) Guidance on the GLP Requirements for Peer Review of Histopathology.科学与监管政策委员会审查:经济合作与发展组织(OECD)关于组织病理学同行评审GLP要求的指南审查。
Toxicol Pathol. 2015 Oct;43(7):907-14. doi: 10.1177/0192623315596382. Epub 2015 Jul 24.
5
Culture of Care: Organizational Responsibilities关怀文化:组织职责
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范(2023年)]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
8
Does GLP enhance the quality of toxicological evidence for regulatory decisions?良好实验室规范(GLP)是否能提高用于监管决策的毒理学证据的质量?
Toxicol Sci. 2016 Jun;151(2):206-13. doi: 10.1093/toxsci/kfw056. Epub 2016 May 5.
9
Scientific and Regulatory Policy Committee Points to Consider: Primary Digital Histopathology Evaluation and Peer Review for Good Laboratory Practice (GLP) Nonclinical Toxicology Studies.科学和监管政策委员会考虑要点:用于良好实验室规范 (GLP) 非临床毒理学研究的主要数字病理评估和同行评审。
Toxicol Pathol. 2022 Jun;50(4):531-543. doi: 10.1177/01926233221099273. Epub 2022 Jun 3.
10
Re: Journal Standards - Editor's reply.关于:期刊标准——编辑回复。
N Z Vet J. 2003 Aug;51(4):199. doi: 10.1080/00480169.2003.36367.

引用本文的文献

1
Hypothesis-driven weight of evidence evaluation indicates ethylbenzene lacks endocrine disruption potential by EATS pathways.基于假设的证据权重评估表明,乙苯通过EATS途径缺乏内分泌干扰潜力。
EXCLI J. 2025 Mar 27;24:479-507. doi: 10.17179/excli2024-7822. eCollection 2025.
2
Does GLP enhance the quality of toxicological evidence for regulatory decisions?良好实验室规范(GLP)是否能提高用于监管决策的毒理学证据的质量?
Toxicol Sci. 2016 Jun;151(2):206-13. doi: 10.1093/toxsci/kfw056. Epub 2016 May 5.
3
NIEHS/FDA CLARITY-BPA research program update.美国国立环境卫生科学研究所/美国食品药品监督管理局双酚A(BPA)清晰研究项目进展报告
Reprod Toxicol. 2015 Dec;58:33-44. doi: 10.1016/j.reprotox.2015.07.075. Epub 2015 Jul 29.
4
Taking financial relationships into account when assessing research.在评估研究时考虑财务关系。
Account Res. 2013;20(3):184-205. doi: 10.1080/08989621.2013.788383.

本文引用的文献

1
Findings of Scientific Misconduct.科学不端行为的调查结果。
Fed Regist. 2001 Oct 12;66(198):52137.
2
Is funding source related to study reporting quality in obesity or nutrition randomized control trials in top-tier medical journals?顶级医学期刊中关于肥胖或营养的随机对照试验中,资金来源与研究报告质量有关吗?
Int J Obes (Lond). 2012 Jul;36(7):977-81. doi: 10.1038/ijo.2011.207. Epub 2011 Nov 8.
3
Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program.基于假设的证据权重框架,用于评估美国环保署内分泌干扰物筛选计划中的数据。
Regul Toxicol Pharmacol. 2011 Nov;61(2):185-91. doi: 10.1016/j.yrtph.2011.07.007. Epub 2011 Jul 23.
4
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research.改进生物科学研究报告:动物研究报告的ARRIVE指南。
J Pharmacol Pharmacother. 2010 Jul;1(2):94-9. doi: 10.4103/0976-500X.72351.
5
Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.评估 EPA 的第 1 层内分泌筛选电池以及改进筛选结果解释的建议。
Regul Toxicol Pharmacol. 2011 Apr;59(3):397-411. doi: 10.1016/j.yrtph.2011.01.003. Epub 2011 Jan 18.
6
Retractions in the scientific literature: is the incidence of research fraud increasing?科学文献中的撤稿:研究造假的发生率在增加吗?
J Med Ethics. 2011 Apr;37(4):249-53. doi: 10.1136/jme.2010.040923. Epub 2010 Dec 24.
7
Enhancing the credibility of decisions based on scientific conclusions: transparency is imperative.提高基于科学结论的决策的可信度:透明度是必要的。
Toxicol Sci. 2010 Jul;116(1):5-7. doi: 10.1093/toxsci/kfq102. Epub 2010 Apr 2.
8
Ensuring integrity in industry-sponsored research: primum non nocere, revisited.确保行业资助研究的诚信:重温“首要不伤害原则”
JAMA. 2010 Mar 24;303(12):1196-8. doi: 10.1001/jama.2010.337.
9
Problems with peer review.同行评审的问题。
BMJ. 2010 Mar 15;340:c1409. doi: 10.1136/bmj.c1409.
10
Good laboratory practices are not synonymous with good scientific practices, accurate reporting, or valid data.良好的实验室规范并非等同于良好的科学实践、准确的报告或有效的数据。
Environ Health Perspect. 2010 Feb;118(2):A60; author reply A61. doi: 10.1289/ehp.0901495.

监管决策中的信息质量:同行评审与良好实验室规范。

Information Quality in Regulatory Decision Making: Peer Review versus Good Laboratory Practice.

机构信息

L.S. McCarty Scientific Research & Consulting, Newmarket, Ontario, Canada.

出版信息

Environ Health Perspect. 2012 Jul;120(7):927-34. doi: 10.1289/ehp.1104277. Epub 2012 Feb 17.

DOI:10.1289/ehp.1104277
PMID:22343028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3404654/
Abstract

BACKGROUND

There is an ongoing discussion on the provenance of toxicity testing data regarding how best to ensure its validity and credibility. A central argument is whether journal peer-review procedures are superior to Good Laboratory Practice (GLP) standards employed for compliance with regulatory mandates.

OBJECTIVE

We sought to evaluate the rationale for regulatory decision making based on peer-review procedures versus GLP standards.

METHOD

We examined pertinent published literature regarding how scientific data quality and validity are evaluated for peer review, GLP compliance, and development of regulations.

DISCUSSION

Some contend that peer review is a coherent, consistent evaluative procedure providing quality control for experimental data generation, analysis, and reporting sufficient to reliably establish relative merit, whereas GLP is seen as merely a tracking process designed to thwart investigator corruption. This view is not supported by published analyses pointing to subjectivity and variability in peer-review processes. Although GLP is not designed to establish relative merit, it is an internationally accepted quality assurance, quality control method for documenting experimental conduct and data.

CONCLUSIONS

Neither process is completely sufficient for establishing relative scientific soundness. However, changes occurring both in peer-review processes and in regulatory guidance resulting in clearer, more transparent communication of scientific information point to an emerging convergence in ensuring information quality. The solution to determining relative merit lies in developing a well-documented, generally accepted weight-of-evidence scheme to evaluate both peer-reviewed and GLP information used in regulatory decision making where both merit and specific relevance inform the process.

摘要

背景

关于如何确保毒理学测试数据的有效性和可信度,人们一直在讨论其来源。一个核心论点是,期刊同行评议程序是否优于为遵守法规要求而采用的良好实验室规范 (GLP) 标准。

目的

我们旨在评估基于同行评议程序与 GLP 标准的监管决策的基本原理。

方法

我们研究了有关同行评议、GLP 合规性以及法规制定如何评估科学数据质量和有效性的相关文献。

讨论

有人认为,同行评议是一种连贯一致的评估程序,为实验数据的生成、分析和报告提供了质量控制,足以可靠地确定相对价值,而 GLP 仅被视为一种跟踪过程,旨在防止研究人员的腐败。这一观点与指向同行评议过程的主观性和可变性的已发表分析并不相符。虽然 GLP 不是为了确定相对价值而设计的,但它是一种国际公认的质量保证、质量控制方法,用于记录实验过程和数据。

结论

这两个过程都不足以完全确定相对科学的合理性。然而,同行评议过程和监管指南都发生了变化,更加清晰透明地传达了科学信息,这表明在确保信息质量方面出现了趋同的趋势。确定相对价值的解决方案在于制定一个有充分记录、普遍接受的证据权重方案,用于评估用于监管决策的同行评议和 GLP 信息,其中价值和具体相关性都为该过程提供信息。